These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 28927521

  • 1. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
    Merkel O, Taylor N, Prutsch N, Staber PB, Moriggl R, Turner SD, Kenner L.
    Mutat Res Rev Mutat Res; 2017 Jul; 773():1-13. PubMed ID: 28927521
    [Abstract] [Full Text] [Related]

  • 2. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G.
    J Hematol Oncol; 2017 Jul 03; 10(1):133. PubMed ID: 28673313
    [Abstract] [Full Text] [Related]

  • 3. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F, Wahl GM.
    Int J Biochem Cell Biol; 2007 Jul 03; 39(7-8):1476-82. PubMed ID: 17499002
    [Abstract] [Full Text] [Related]

  • 4. An Update on MDMX and Dual MDM2/X Inhibitors.
    Espadinha M, Barcherini V, Lopes EA, Santos MMM.
    Curr Top Med Chem; 2018 Jul 03; 18(8):647-660. PubMed ID: 29866007
    [Abstract] [Full Text] [Related]

  • 5. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
    Shuvalov OY, Fedorova OA, Petukhov AV, Daks AA, Vasilieva EA, Grigorieva TA, Ivanov GS, Barlev NA.
    Tsitologiia; 2015 Jul 03; 57(12):847-54. PubMed ID: 26995961
    [Abstract] [Full Text] [Related]

  • 6. Regulation of p53: a collaboration between Mdm2 and Mdmx.
    Pei D, Zhang Y, Zheng J.
    Oncotarget; 2012 Mar 03; 3(3):228-35. PubMed ID: 22410433
    [Abstract] [Full Text] [Related]

  • 7. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
    Wade M, Wahl GM.
    Mol Cancer Res; 2009 Jan 03; 7(1):1-11. PubMed ID: 19147532
    [Abstract] [Full Text] [Related]

  • 8. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
    Toledo F, Wahl GM.
    Nat Rev Cancer; 2006 Dec 03; 6(12):909-23. PubMed ID: 17128209
    [Abstract] [Full Text] [Related]

  • 9. Targeting p53-MDM2-MDMX loop for cancer therapy.
    Zhang Q, Zeng SX, Lu H.
    Subcell Biochem; 2014 Dec 03; 85():281-319. PubMed ID: 25201201
    [Abstract] [Full Text] [Related]

  • 10. The p53 orchestra: Mdm2 and Mdmx set the tone.
    Wade M, Wang YV, Wahl GM.
    Trends Cell Biol; 2010 May 03; 20(5):299-309. PubMed ID: 20172729
    [Abstract] [Full Text] [Related]

  • 11. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT.
    Cell Cycle; 2008 Jun 01; 7(11):1604-12. PubMed ID: 18520179
    [Abstract] [Full Text] [Related]

  • 12. p53 as a target for the treatment of cancer.
    Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM.
    Cancer Treat Rev; 2014 Dec 01; 40(10):1153-60. PubMed ID: 25455730
    [Abstract] [Full Text] [Related]

  • 13. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Gao C, Xiao G, Piersigilli A, Gou J, Ogunwobi O, Bargonetti J.
    Breast Cancer Res; 2019 Jan 14; 21(1):5. PubMed ID: 30642351
    [Abstract] [Full Text] [Related]

  • 14. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
    Golestanian S, Sharifi A, Popowicz GM, Azizian H, Foroumadi A, Szwagierczak A, Holak TA, Amanlou M.
    Life Sci; 2016 Jan 15; 145():240-6. PubMed ID: 26746660
    [Abstract] [Full Text] [Related]

  • 15. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ, Dong DF, Chen NZ, Wu YY, Li EX, Wang J, Wang SM.
    Int J Oncol; 2013 Dec 15; 43(6):1935-42. PubMed ID: 24126697
    [Abstract] [Full Text] [Related]

  • 16. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q, Li Y, Mu K, Li Z, Meng Q, Wu X, Wang Y, Li L.
    Diagn Pathol; 2014 Mar 25; 9():71. PubMed ID: 24667108
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
    Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollè G, Sanfilippo R, Gronchi A, Perrone F, Tamborini E, Pelosi G, Pierotti MA, Maestro R, Pricl S, Pilotti S.
    Lab Invest; 2013 Nov 25; 93(11):1232-40. PubMed ID: 24018792
    [Abstract] [Full Text] [Related]

  • 18. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
    Park DE, Cheng J, Berrios C, Montero J, Cortés-Cros M, Ferretti S, Arora R, Tillgren ML, Gokhale PC, DeCaprio JA.
    Proc Natl Acad Sci U S A; 2019 Jan 15; 116(3):1027-1032. PubMed ID: 30598450
    [Abstract] [Full Text] [Related]

  • 19. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
    Cai X, Yuan ZM.
    J Comput Biol; 2009 Jul 15; 16(7):917-33. PubMed ID: 19580521
    [Abstract] [Full Text] [Related]

  • 20. Mdmx promotes genomic instability independent of p53 and Mdm2.
    Carrillo AM, Bouska A, Arrate MP, Eischen CM.
    Oncogene; 2015 Feb 12; 34(7):846-56. PubMed ID: 24608433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.